<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989612</url>
  </required_header>
  <id_info>
    <org_study_id>113519</org_study_id>
    <nct_id>NCT00989612</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Influenza Candidate Vaccine GSK2340274A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK
      Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged
      20-64 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Protocol Posting has been updated following Protocol amendment 1&amp; 2, October 2009. The
      sections impacted are study design and outcome measures
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for serum Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers for serum Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 21</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers for serum Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 42</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seropositive subjects for Haemagglutination Inhibition (HI) antibodies A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0</time_frame>
    <description>A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seropositive subjects for Haemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seropositive subjects for Haemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroconverted subjects for Haemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroconverted subjects for Haemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroprotected subjects against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroprotected subjects against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroprotected subjects against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion factor for Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 21</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion factor for Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 42</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of seropositive subjects for Haemagglutination Inhibition (HI) antibodies A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0 (PRE), 21, 42 and 182</time_frame>
    <description>A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for serum Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0 (PRE), 21, 42 and 182</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroconverted subjects for Haemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Days 21, 42 and 182</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroprotected subjects against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0 (PRE), 21, 42 and 182</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion factor for Hemagglutination Inhibition (HI) antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 21, 42 and 182</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for serum neutralizing antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0 (PRE), 21, 42 and 182</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seropositive subjects for neutralizing antibodies A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0 (PRE), 21, 42 and 182</time_frame>
    <description>A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroconverted subjects for neutralizing antibodies against A/California/7/2009 (H1N1)v-like antigen</measure>
    <time_frame>At Day 0 (PRE), 21, 42 and 182</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with a minimum 4-fold increase in post vaccination neutralizing titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any and Grade 3 solicited local symptoms</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up after each vaccination</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any, Grade 3 and related solicited general symptoms</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up after each vaccination</time_frame>
    <description>Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any, Grade 3 and related unsolicited adverse events (AEs)</measure>
    <time_frame>During a 21-day (Day 0-20) follow-up period after the first vaccination and during a 63-day (Day 21-84) follow-up after the second vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious adverse events (SAEs)</measure>
    <time_frame>During the entire study period (Day 0-182)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any adverse events of specific interest (AESIs).</measure>
    <time_frame>During the entire study period (Day 0-182)</time_frame>
    <description>An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with any solicited local symptoms</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up after each vaccination</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with any solicited general symptoms</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up after each vaccination</time_frame>
    <description>Assessed solicited general symptoms were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK2340274A GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza investigational vaccine GSK2340274A</intervention_name>
    <description>Two intramuscular injections on Day 0 and Day 21, respectively</description>
    <arm_group_label>GSK2340274A GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male and female adults 20 to 64 years of age at time of the first
             vaccination, inclusive.

          -  Good general health as assessed by medical history and physical examination

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  Written informed consent obtained from the subject.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line or mobile, but NOT a pay phone or other multiple-user
             device.

          -  Females of non-childbearing potential may be enrolled in the study.

          -  Female of childbearing potential may be enrolled in the study, if she:

          -  has practiced adequate contraception for 30 days prior to vaccination, and

          -  has a negative pregnancy test on the day of vaccination, and

          -  has agreed to continue adequate contraception during the entire treatment period and
             for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  History of previous administration of a novel [H1N1]v vaccine.

          -  Previous participation in study NCT00742885.

          -  Presence of significant acute or chronic, uncontrolled medical or psychiatric illness.

          -  Presence or evidence of substance abuse or of neurological or psychiatric diagnoses
             which, although stable, are deemed by the investigator to render the potential subject
             unable/unlikely to provide accurate safety reports.

          -  Presence of an axillary temperature &gt;= 37.5 °C, or acute symptoms greater than &quot;mild&quot;
             severity on the scheduled date of first vaccination.

          -  Diagnosed with cancer, or treatment for cancer within 3 years.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including
             history of human immunodeficiency virus (HIV) infection.

          -  Chronic administration of immunosuppressants or other immune modifying drugs within 6
             months of study enrolment or planned administration during the study period.

          -  Receipt of any immunoglobulins and/or any blood products within 3 months of study
             enrolment or planned administration of any of these products during the study period.

          -  Any significant disorder of coagulation or treatment with warfarin derivatives or
             heparin.

          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome.

          -  Administration of any vaccines within 30 days before vaccination or planned
             administration within the first vaccination up to blood sampling at Day 42 and within
             30 days prior to blood sampling at Day 182, with the exception of seasonal influenza
             vaccine.

          -  Administration of any seasonal influenza vaccine within 14 days before vaccination on
             Day 0, or planned administration within the first vaccination up to blood sampling at
             Day 42 and within 14 days prior to blood sampling at Day 182.

          -  Any known or suspected allergy to any constituent of influenza vaccines or component
             used in the manufacturing process of the study vaccine; a history of anaphylactic-type
             reaction to any constituent of influenza vaccines; or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  Known pregnancy or a positive urine test result prior to the time of first
             vaccination.

          -  Lactating or nursing female.

          -  Excessive underweight (Body Mass Index [BMI] &lt; 18.5) or excessive obesity (BMI &gt;= 30).

          -  Any conditions which, in the opinion of the investigator, prevents the subjects from
             participating in the study.

          -  Clinically or virologically confirmed influenza infection within 6 months preceding
             the study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <disposition_first_submitted>July 2, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2010</disposition_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza infection</keyword>
  <keyword>GSK Biologicals' influenza vaccine GSK2340272A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113519</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>April 14, 2017</submitted>
    <returned>July 11, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

